AI-Powered Discovery Of T-Cell-Receptor-Based Cancer Immunotherapies

Data
In-house generation of massive TCR-target interaction datasets using cutting-edge
high-throughput screening techniques

Model
In silico predictions of TCR-target interactions through deep learning models trained on our proprietary datasets

Discover
Discovery of novel tumour targets shared across patients and safe and effective target-specific TCRs
Our team

Federico Paoletti
CEO and CO-FOUNDER
PhD in Molecular and Computational Oncology (University of Oxford, UK) and deep expertise in mathematical modelling and molecular biophysics. Previously worked at the World Health Organisation assessing cancer prevention strategies.

Andrea Mambrini
CTO and CO-FOUNDER
PhD in Bio-Inspired Computation (University of Birmingham, UK) and several years of hands-on experience building cutting-edge AI software tools across the space, media, automotive and marketing industries.

Alasdair Thong
Commercial Advisor
Founding partner at Selvedge Venture. Ex-director of deep-tech venture investments at Leaps for Bayer. Extensive experience negotiating and managing AI-driven co-development partnerships in the biopharmaceutical industry.

Email:
info@exogene.co.uk
Reg. Number:
12293407
Address:
Exogene Limited, Internatonal House, 24 Holborn Viaduct, EC1A 2BN, London, United Kingdom